Alice Herlihy, MD
Pulmonary Disease · North Chesterfield, VANPI 1902013196
Payments from drug & device makers
What this record shows
This record is dominated by education: $12,018 of the $18,471 with a category attached, or 65.1%. Intuitive Surgical accounts for 70.9% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $14,187 and has fallen 88.3% since, to $1,653 in 2025.
Across 298 payments — averaging $61.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$13K
- AstraZeneca$1K
- GSK$816
- Sanofi$509
- Genentech USA, Inc.$304
- Grifols USA, LLC$280
- plus $2K from 30 others
What the payments were for
- Travel & lodging$9855%
- Food & beverage$5,46930%
- Education$12,01865%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $13,098 |
| AstraZeneca | 32 | $1,059 |
| GSK | 71 | $816 |
| Sanofi | 29 | $509 |
| Genentech USA, Inc. | 17 | $304 |
| Grifols USA, LLC | 12 | $280 |
| Boehringer Ingelheim | 12 | $238 |
| Amgen | 12 | $212 |
| Philips North America LLC | 12 | $187 |
| Paratek Pharmaceuticals, Inc. | 10 | $173 |
| Insmed, Inc. | 10 | $157 |
| Regeneron Healthcare Solutions, Inc. | 8 | $149 |
| Actelion Pharmaceuticals US, Inc. | 7 | $148 |
| Mallinckrodt Hospital Products Inc. | 5 | $127 |
| ANI Pharmaceuticals, Inc. | 4 | $124 |
| Mylan Specialty L.p. | 7 | $114 |
| Inogen, Inc. | 4 | $88 |
| Merck | 3 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $65 |
| Sunovion Pharmaceuticals Inc. | 3 | $56 |
| Vifor Pharma, Inc. | 3 | $56 |
| Pulmonx Corporation | 2 | $51 |
| Novartis | 3 | $48 |
| Covis Pharma GmbH | 2 | $48 |
| Pfizer | 2 | $41 |
| United Therapeutics Corporation | 2 | $38 |
| Baxter Healthcare | 2 | $34 |
| Atricure, Inc. | 1 | $34 |
| 3b Medical, Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Biogen | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Sandoz | 1 | $12 |
| Bayer | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,471 in reported general payments places this provider in the 85th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 673 | $600,929 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 229 | $179,243 |
| Dupixent SyringeDupilumab | 36 | $154,736 |
| Spiriva RespimatTiotropium Bromide | 225 | $140,482 |
| Breo ElliptaFluticasone/Vilanterol | 207 | $126,000 |
| Dupixent PenDupilumab | 27 | $109,528 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 126 | $88,995 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 141 | $70,939 |
| XolairOmalizumab | 26 | $62,688 |
| SymbicortBudesonide/Formoterol Fumarate | 152 | $48,021 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 163 | $26,827 |
| EliquisApixaban | 40 | $25,902 |
| Spiriva HandihalerTiotropium Bromide | 29 | $23,039 |
| DuleraMometasone/Formoterol | 35 | $19,718 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 601 | $18,677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $816 | $823,7051,085 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $238 | $241,667371 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,059 | $227,264381 claims |
| PfizerEliquis | $41 | $25,90240 claims |
| MerckDulera | $87 | $19,71835 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $13 | $1,13117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in North Chesterfield
- Adam KaiserNorth Chesterfield$67K
- Muhammad AtharNorth Chesterfield$25K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.